Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.68, $0.35 better than the analyst estimate of $0.33. Revenue for the quarter came in at $30.5 million versus the consensus estimate of $27.9 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.